Biotherapeutics discovery and development
This article was originally published in Start Up
Inhibrx LLC focuses on biologic therapeutic development in areas where there are unmet needs for novel or better drugs, and where the preclinical models clearly demonstrate the potential for success in the clinic. Its model is to license its programs to pharmaceutical and biotech companies for clinical development and commercialization, with no plans to carry out those steps on its own.
You may also be interested in...
Private Company Edition: Venture capital for emerging therapeutics companies in the US and in ex-US regions reached all-time highs in 2018. Also, Alphamab raises $60m Series B, three new VC funds launch and FLX changes its name to RAPT.
Gene editing has made a great many headlines of late, and one could be forgiven for thinking the field was saturated, but Homology Medicines Inc. offers something new. Its platform relies on a different mechanism, known as homologous recombination, and the start-up's management team believes the approach can get around some of the potential limitations found in other gene-editing technologies.
X4 Pharmaceuticals Inc. spun out from Sanofi to develop compounds that target the CXCR4/CXCL12 receptor pathway to restore immune cell surveillance against cancer.